donor-derived CD7 CAR-T cells

This investigational donor-derived CD7 CAR-T cell therapy is being developed by Zhejiang University as a novel bridging strategy for patients with severe aplastic anemia (SAA) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The therapy consists of T-cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the CD7 antigen, a glycoprotein expressed on the majority of T-cells and natural killer (NK) cells. By targeting and eliminating CD7-positive cells, the therapy leverages the resulting immunosuppressive environment to facilitate donor cell engraftment during subsequent transplantation. This approach is intended to potentially eliminate the need for traditional intensive pharmacologic conditioning regimens or graft-versus-host disease (GVHD) prophylaxis.

Other names

CD7 CAR-T cells injectionCD-7 CAR-T cells injectionCD 7 CAR-T cells injectionCD7-targeted CAR-T cellsCD-7-targeted CAR-T cellsCD 7-targeted CAR-T cells